AZITHROMYCIN-D3
- CAS No.
- 163921-65-1
- Chemical Name:
- AZITHROMYCIN-D3
- Synonyms
- XZ-450-d3;Sumamed-d3;Ribotrex-d3;CP-62993-d3;Zitromax-d3;Zithromaz-d3;Trozocina-d3;Azitrocin-d3;AZITHROMYCIN-D3;D3-Azithromycin
- CBNumber:
- CB5648148
- Molecular Formula:
- C38H72N2O12
- Molecular Weight:
- 748.98448
- MDL Number:
- MFCD09839972
- MOL File:
- 163921-65-1.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 20675 | 1mg | $325 |
| Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 20675 | 5mg | $1298 |
| Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 20675 | 10mg | $2110 |
| Azithromycin-d3 ≥99% deuterated forms (d1-d3) | 20675 | 1mg | $287 |
| Azithromycin-d3 (CP-62993-d3, XZ-450-d3, Azitrocin-d3, Ribotrex-d3, Sumamed-d3, Trozocina-d3, Zithromaz-d3, Zitromax-d3) ChemicalPurity:~90%|IsotopicPurity:~90% | A5050-01 | 1mg | $475 |
| More product size | |||
| Melting point | 125-1290C |
|---|---|
| storage temp. | -20°C Freezer, Under Inert Atmosphere |
| solubility | Chloroform (Slightly, Sonicated), Methanol (Slightly) |
| form | Solid |
| color | White to Off-White |
| EPA Substance Registry System | 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-6-(methyl-d3)-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (163921-65-1) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H317-H334 |
| Precautionary statements | P261-P272-P280-P284-P302+P352-P304+P340-P333+P313-P342+P311-P362+P364-P501 |
AZITHROMYCIN-D3 price More Price(22)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 20675 | Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 163921-65-1 | 1mg | $325 | 2026-04-30 | Buy |
| Cayman Chemical | 20675 | Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 163921-65-1 | 5mg | $1298 | 2026-04-30 | Buy |
| Cayman Chemical | 20675 | Azithromycin-d3 ≥99%deuteratedforms(d1-d3) | 163921-65-1 | 10mg | $2110 | 2026-04-30 | Buy |
| Cayman Chemical | 20675 | Azithromycin-d3 ≥99% deuterated forms (d1-d3) | 163921-65-1 | 1mg | $287 | 2024-03-01 | Buy |
| Usbiological | A5050-01 | Azithromycin-d3 (CP-62993-d3, XZ-450-d3, Azitrocin-d3, Ribotrex-d3, Sumamed-d3, Trozocina-d3, Zithromaz-d3, Zitromax-d3) ChemicalPurity:~90%|IsotopicPurity:~90% | 163921-65-1 | 1mg | $475 | 2026-06-03 | Buy |
AZITHROMYCIN-D3 Chemical Properties,Uses,Production
Description
Azithromycin-d3 is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. Azithromycin is a macrolide antibiotic. It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively). It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μM. Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg. Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.
Chemical Properties
White Solid
Uses
AzithroMycin-d3 can be used as Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.;AzithroMycin-d3 can be intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry.
IC 50
Macrolide
References
[1] M S KANATANI B J G. The new macrolides. Azithromycin and clarithromycin.[J]. The Western journal of medicine, 1994, 160 1: 31-37.
[2] D GIRARD. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.[J]. Journal of Antimicrobial Chemotherapy, 2005, 56 2: 365-371. DOI: 10.1093/jac/dki241
[3] AHMED MOSTAFA. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.[J]. ACS Applied Energy Materials, 2020. DOI: 10.3390/ph13120443
[4] ANASUYA PATEL. Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis.[J]. ACS Applied Energy Materials, 2018. DOI: 10.1128/aac.00752-18
AZITHROMYCIN-D3 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19936 | 58 |
| HANGZHOU LEAP CHEM CO., LTD. | +86-571-87711850 | market18@leapchem.com | China | 43333 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 52923 | 58 | |
| Artis Biotech Co. Ltd. | 18108108965 18108108965 | sales@artisbio.com | China | 2450 | 58 |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chemsky（shanghai）International Co.,Ltd. | 021-50135380 | shchemsky@sina.com | China | 32321 | 50 |
| S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-83725681-603 | China | 4496 | 50 | |
| Shanghai TaoSu Biochemical Technology Co., Ltd. | 021-33632979 | info@tsbiochem.com | China | 8065 | 58 |
| Alta Scientific Co., Ltd. | 022-6537-8550 15522853686 | sales@altasci.com.cn | China | 4511 | 55 |
| Clearsynth Canada Inc. | +1.415.685.4395 | enquiry@clearsynth.com | Canada | 912 | 58 |
163921-65-1(AZITHROMYCIN-D3)Related Search:
1of4
